Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, February 21, 2021

Hypothyroidism in Head and Neck Squamous Cell Carcinoma Patients Receiving Radiotherapy With or Without Immune Checkpoint Inhibitors

xlomafota13 shared this article with you from Inoreader

Objectives/Hypothesis

Hypothyroidism is a relatively common complication of head and neck squamous cell carcinoma (HNSCC) treatment. The objective of this study was to determine whether the addition of programmed death ligand‐1 (PD‐1) or programmed death ligand‐1 (PD‐L1) inhibition (anti‐PD‐1/PD‐L1 therapy) to standard treatment increases the risk of hypothyroidism in HNSCC.

Study Design

Retrospective Cohort.

Methods

This is a retrospective, single institutional cohort study. Patients who received radiotherapy (RT) for HNSCC were identified in the electronic medical record. Patient factors collected include age, sex, body mass index (BMI), smoking status, alcohol use, Charlson comorbidity index, and HNSCC treatment records. The rate of hypothyroidism for patients with HNSCC receiving RT (+/− chemotherapy and surgery) (RT group, n = 101) was compared to that of HNSCC patients receiving RT (+/− chemotherapy and surgery) + anti‐PD‐1/PD‐L1 therapy, either concurrently or after RT (RT + anti‐PD‐1/PD‐L1 group, n = 38).

Results

There was no significant difference in the rate of clinical or subclinical hypothyroidism between the two groups. Multinomial logistic regression found no significant difference in hypothyroidism based on age, sex, or BMI.

Conclusions

The addition of anti‐PD‐1/PD‐L1 therapy to standard HNSCC treatment does not significantly increase the risk of developing hypothyroidism.

Level of Evidence

3 Laryngoscope, 2021

View on the web

No comments:

Post a Comment